April 20, 2026   |   Read online Tuesday’s Watchlist: (GCTK) is in Focus Tomorrow Morning Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Market Maven Insights Initiates Coverage On GlucoTrack, Inc. (Nasdaq: GCTK) Starting Tomorrow Morning—Tuesday, April 21, 2026 Don’t miss the next breakout — get real-time alerts sent straight to your phone! Full Coverage Will Be Starting Early. Consider Starting Your Own Research On (GCTK) While It’s Still Early…  April 20, 2026 Tuesday’s Watchlist: (GCTK) is in Focus Tomorrow Morning Dear Reader, Most people don’t think twice about how glucose is tracked, until they see how often it has to be managed. A small patch. Worn on the arm. Replaced every 10–14 days. For millions living with diabetes, that cycle is constant. But GlucoTrack, Inc. (Nasdaq: GCTK) is working toward something very different, a fully implantable continuous blood glucose monitor designed to operate for years, without any external wearable. No patch. No routine replacements. No visible device. Instead, a system built for long-term, continuous monitoring beneath the skin. With early human data already completed and an FDA IDE submission targeted for Q2 2026, the company is now entering a more critical stage of development—and beginning to draw attention. Here’s where it gets interesting. (GCTK) is developing a long-duration implantable solution that removes the need for traditional on-body CGM systems altogether—positioning it within a rapidly evolving segment of diabetes care. That’s why (GCTK) is moving to the top of our watchlist heading into Tuesday, April 21, 2026. For now, the name still appears to be under the radar, trading below $1 as of this week. But the structure stands out. (GCTK) has roughly 1.0M–1.8M shares outstanding, with a sub-1M public float—a setup that can react quickly as volume begins to build. And we’ve already seen a glimpse of that. Recently, (GCTK) made an approximate 53% move in under a week, climbing from around $0.65 on April 9 to $1.00 on April 13. Now, with multiple factors starting to align, it’s beginning to show up on our radar. That combination, a differentiated device, early human data, and a development timeline that is beginning to tighten, is what’s starting to bring (GCTK) into clearer focus for us. In a space largely dominated by wearable systems, a company pursuing a fully implantable alternative naturally stands apart. Layer in a tightly held float and a recent move that already showed this name can react quickly, and it becomes easier to see why attention could begin to shift. In other words, this is no longer just a concept, it’s a developing story that may be entering a phase where the market starts paying closer attention. With an FDA IDE submission targeted for Q2 2026 and a U.S. clinical trial expected in the second half of 2026, (GCTK) is positioning itself as a name to watch within the medtech diabetes space. To understand why, it’s worth taking a closer look at what (GCTK) is building—and how its approach differs from the systems patients rely on today. Inside (GCTK): The Technology and Strategy Driving Its Next Phase GlucoTrack, Inc. (Nasdaq: GCTK) is a New Jersey–based medical technology company focused on developing next-generation solutions for diabetes management. At the center of its pipeline is a Continuous Blood Glucose Monitor (CBGM)—a long-term, fully implantable system designed to measure glucose directly from the bloodstream rather than interstitial fluid. By targeting blood-based readings, the platform is built to reduce the lag time commonly seen with traditional wearable CGMs. The system is being developed with a target lifespan of up to three years, minimal calibration requirements, and no external wearable component—addressing many of the friction points associated with patches, adhesives, and frequent sensor replacements. This positions (GCTK) in a unique lane. While most current solutions rely on short-duration, skin-mounted sensors lasting 10–14 days, and more invasive implantable options can be complex, (GCTK)’s approach is designed to bridge that gap with a long-duration, low-maintenance alternative. From a progress standpoint, the company has already: Completed a first-in-human study Advanced follow-up feasibility work internationally Secured three U.S. patents tied to its core technology Established a U.S. clinical trial site and engaged a CRO All of which leads into a key next step: an FDA IDE submission targeted for Q2 2026, marking a transition into the next phase of clinical development. The Market Backdrop: A Growing Global Health Challenge The scope of diabetes worldwide continues to expand at a significant pace. According to the International Diabetes Federation, an estimated 589M adults are currently living with diabetes—a number projected to climb to 700M by 2045. The economic impact is just as substantial. Global health expenditures tied to diabetes have reached approximately $1 trillion, representing a 338% increase over the past 17 years. As both prevalence and costs continue to rise, the demand for more efficient, long-term management solutions is becoming increasingly critical. Against that backdrop, the global CGM market was valued at approximately $13.3B in 2025 and is projected to grow to $31.4B by 2031 at a 15.4% CAGR, making it one of the fastest-growing segments in all of medical devices. Today's market is dominated by wearable subcutaneous sensors from Abbott, Dexcom, and Medtronic—three companies that collectively controlled over 98% of 2025 shipments according to Mordor Intelligence.  But every one of their devices requires periodic on-body replacement.  (GCTK) is targeting the patient population that wants continuous monitoring without the daily or biweekly maintenance burden.  That represents a genuinely differentiated niche within a rapidly expanding market. Clinical Progress & Regulatory Momentum (GCTK)’s development pathway is now entering a more pivotal stage. The company has already completed its first-in-human study, conducted in São Paulo, Brazil between December 2024 and January 2025, marking an important early step in validating its implantable system. The 5-day in-hospital study enrolled 10 participants with Type 1 or Type 2 diabetes on intensive insulin therapy. Results were compelling: a Mean Absolute Relative Difference (MARD) of 7.7% across 122 matched pairs, a 99% data capture rate, and zero procedure- or device-related serious adverse events.  The study met all primary and secondary endpoints. In July 2025, the company initiated a multicenter feasibility study in Australia at St. Vincent's Hospital in Melbourne.  Learnings from that study have been incorporated into product design iterations ahead of the U.S. program.  A U.S. clinical site has been secured, a CRO has been engaged, and the company confirmed it expects to file its Investigational Device Exemption (IDE) with the FDA in Q2 2026, targeting a U.S. trial launch in the second half of 2026, subject to FDA approval. Strengthening the Foundation: IP Protection and Capital Strategy In October and November 2025, the USPTO issued three critical patents for (GCTK)'s CBGM platform (Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258), covering proprietary sensor chemistry, intravascular lead design, and low-power electronics.  These patents protect the core innovations that differentiate (GCTK)'s system from both short-lived subcutaneous sensors and larger, more invasive implantable devices. On the financial side, (GCTK) reported $7.4M in ca-sh and ca-sh equivalents as of December 31, 2025, up from $5.6M at the prior year-end, aided by a $4.0M private placement completed in December 2025.  Full-year 2025 R&D expenses were $9.8M, reflecting continued investment in product design, manufacturing, and preclinical work.  The company stated that existing cash is sufficient to fund its 2026 operating plan through at least the end of Spring 2026—covering the IDE submission.  Management has assembled a leadership team with deep backgrounds at Dexcom, Abbott, Senseonics, and Medtronic. 7 Reasons Why (GCTK) Is Moving to the Top of Our Watchlist — Tuesday, April 21, 2026 Implantable Advantage: (GCTK) is developing a fully implantable continuous glucose monitor designed for multi-year use—eliminating the need for on-body wearables used in traditional systems. Tight Float Structure: With fewer than 1.8M shares available to the public, the company maintains a small float that can respond quickly as interest builds. Recent Action: The stock recently made an approximate 53% move in under a week, climbing from around $0.65 on April 9 to $1.00 on April 13. Early Clinical Data: Initial results reported a 7.7% MARD, 99% data capture rate, and zero serious device- or procedure-related adverse events across 122 matched pairs. Defined FDA Timeline: The company is targeting an IDE submission in Q2 2026, with a U.S. clinical trial planned for the second half of 2026, creating a clear near-term roadmap. Patent Coverage: Three issued U.S. patents provide protection across key components of the platform, including sensor chemistry, intravascular design, and low-power electronics. Expanding Market Opp: (GCTK) is targeting a segment within the CGM market projected to grow from approximately $13.3B in 2025 to $31.4B by 2031, focusing on long-term monitoring without frequent device replacement.  Take A Look At (GCTK) Before Tomorrow Morning… When you zoom out, the setup here starts to come into focus. (GCTK) is developing a fully implantable continuous glucose monitor designed for long-term use—without the external wearable component required by today’s standard systems. That alone puts it in a different category. Then there’s the structure. With fewer than 1.8M shares available to the public, (GCTK) maintains a tight float that can react quickly as demand shifts. We’ve already seen a glimpse of that, with the stock making an approximate 53% move from ~$0.65 to $1.00 in under a week. Behind the story, there’s also measurable progress. Early clinical data reported a 7.7% MARD, 99% data capture rate, and zero serious device- or procedure-related adverse events across 122 matched pairs. Now layer in timing. An IDE submission is targeted for Q2 2026, with a U.S. clinical trial expected in the second half of 2026, alongside three issued U.S. patents protecting key parts of the platform. Put it all together, and (GCTK) is starting to look like a name worth watching more closely. We’ll have all eyes on (GCTK) tomorrow morning. Take a look before the close—and keep an eye out for the next update. Sincerely, Tate Remington Chief Editor, Market Maven Insights MarketMavenInsights.com (“MarketMavenInsights” or “MMI”) is owned by Source Coastal Media LLC, a multi member limited liability company. Data is provided from third-party sources and MMI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MMI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. Pursuant to an agreement between Source Coastal Media LLC and TD Media LLC, Source Coastal Media LLC has been hired for a period beginning on 04/20/2026 and ending on 04/21/2026 to publicly disseminate information about (GCTK:US) via digital communications. Under this agreement, TD Media LLC has paid Source Coastal Media LLC six thousand two hundred fifty USD (“Funds”). To date, including under the previously described agreement, Source Coastal Media LLC has been paid thirteen thousand seven hundred fifty USD (“Funds”). These Funds were part of the nineteen thousand USD funds that TD Media LLC received from a third party named Interactive Offers LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Source Coastal Media LLC, TD Media LLC and their member own shares of (GCTK:US). Please see important disclosure information here: https://marketmaveninsights.com/disclosure/gctk-qCfGt/#details   Update your email preferences or unsubscribe here © 2026 Market Maven Insights 1691 Forum Place Ste B #332 West Palm Beach, Florida 33401, United States Terms of Service

Breaking News Springs (Nasdaq: INBS) For Monday's Spotlight (Early Green Surge)

Intelligent Bio Solutions Inc. (Nasdaq: INBS) is earning our complete focus early Monday.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Breaking News Springs (Nasdaq: INBS) For Monday's Spotlight (Early Green Surge) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* April 20th Greetings, Friend! Intelligent Bio Solutions Inc. (Nasdaq: INBS) is earning our complete focus early Monday. Going green out of the bell, the company could start attracting attention following breaking news. Take a look: Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes U.S. Roadside drug testing market projected to reach $1.62Bn by 2030 NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the launch of a validation study aimed at significantly reducing the analysis time of its Intelligent Fingerprinting Drug Screening System. The study aims to improve the already rapid time-to-result of INBS's drug screening technology, which collects samples in under a minute and provides results within ten minutes at the point of collection. Faster results will enable INBS to target the global roadside drug testing market with a first-in-class solution. "Speed matters in drug screening and is critical for roadside law enforcement,” said Harry Simeonidis, President and CEO at INBS. “Moving from a ten-minute test to under three minutes changes the entire value equation for our customers. This validation study aims to confirm our encouraging preliminary findings and advance us toward our two-minute test goal.” ... Read the full article here. Remember. INBS is a low float idea. With fewer than 2Mn shares in its float, the potential for heightened volatility cannot be ignored. Review my initial (Nasdaq: INBS) report below and consider this idea for your radar. ----- A past champ just popped back up on our radar... Alerted last summer, this profile surged from an open of $1.28 to a high of $2.25 in the short term. That run of approximately 74% showed explosive potential from an under-the-radar idea. Even better, when I released this profile back in December of 2025, it ran from an open on the 18th of $6.23 to a high of $24.90 on January 12th for a move of approx. 299% short term. Now, following a huge news announcement this past Friday, this Nasdaq profile has quickly grabbed our attention again. And with this profile's float of fewer than 2Mn shares meaning volatility potential could be significantly heightened on daily basis, we're bringing it back into focus for radar consideration: Intelligent Bio Solutions Inc. (Nasdaq: INBS) Intelligent Bio Solutions Inc. is rapidly emerging as a leader in the medical technology sector, pioneering non-invasive, real-time point-of-care testing solutions that are reshaping how drug screening and diagnostics are conducted worldwide. With a focus on pain-free, accessible, and accurate testing, the company is positioned at the forefront of a global movement toward more humane and efficient healthcare technologies. Company Overview Founded in 2016 and headquartered in New York, Intelligent Bio Solutions Inc. is committed to leveraging advanced technology to develop transformative solutions that improve quality of life. The company’s mission is to redefine the approach to testing by delivering pain-free, accessible solutions that drive transformative change across healthcare and workplace safety. Core Technologies and Products Intelligent Fingerprinting Drug Testing Solution At the heart of INBS’s innovation is the Intelligent Fingerprinting Drug Testing Solution. This system utilizes a patented technology that analyzes sweat collected from the fingertips to detect recent drug use-including cann-a-bis, co-caine, o-piate-s, and me-thamp-heta-mine-within the preceding 16–24 hours. The process is non-invasive, requiring less than a minute for sample collection and delivering results in under ten minutes. Key advantages include: Dignified, Non-Invasive Collection: No need for blood, urine, or saliva samples, reducing discomfort and privacy concerns. Rapid Results: Enables timely decision-making in workplace, clinical, and law enforcement settings. Portability and Ease of Use: Designed for use in the field, workplaces, and clinics, with minimal training required. Hygienic and Cost-Effective: Reduces biohazard risks and maintenance costs, with annual calibration sufficing for ongoing use. Regulatory Milestones And U.S. Market Entry A significant milestone was achieved with the submission of the FDA 510(k) pre-market notification for the Intelligent Fingerprinting Drug Screening System in December 2024. The company’s clinical studies have demonstrated high sensitivity, specificity, and usability, with performance data showing 94.1% accuracy and pharmacokinetic studies confirming the reliability of fingerprint sweat as a matrix for drug detection. INBS is on track for a planned expansion into the multi-Bn dollar U.S. market in 2026, targeting a region that accounts for approximately 28% of the global drug screening market. The rising rates of drug positivity in the U.S. workforce-particularly in safety-sensitive industries-underscore the urgent need for effective, rapid, and non-invasive testing solutions like those offered by INBS. Intellectual Property and Competitive Position INBS’s technology is protected by a robust intellectual property portfolio, including six U.S. patents covering the lateral flow test strip, sample collection cartridge, cartridge housing, and buffer clip design. This IP protection strengthens the company’s competitive position as it prepares for broader commercialization and future product development. Market Opp. And Future Outlook Why Take A Closer Look? Intelligent Bio Solutions Inc. stands out for several compelling reasons: Innovative, Patented Technology: Non-invasive, rapid, and highly accurate testing solutions with strong IP protection. Proven Market Acceptance: Operational in at least 19 countries with a growing base of over 480 customer accounts. Strong Financial Trajectory: Demonstrated revenue and margin growth, with a scalable, recurring revenue model. Strategic Global Expansion: Active in high-growth markets and sectors, with multilingual capabilities and key partnerships. Clear Path to U.S. Market: On track for potential FDA clearance and entry into the world’s largest drug screening market in 2025. Vision for Broader Diagnostics: Versatile biosensor platform poised for future applications in clinical diagnostics. ----- Five (Nasdaq: INBS) Potential Catalysts To Consider #1. A Low Float - INBS has a very low float of roughly 1.53Mn shares. This means volatility potential may be heightened on a daily basis. #2. An Analyst $12 Target - As of April 17th, Ladenburg Thalmann Co. Inc. was reporting a $12 target on INBS. From its closing valuation on Friday, that target is suggesting INBS to have over 300% potential upside. #3. Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified. Intelligent Bio Solutions announced successful penetration testing supporting its upcoming FDA 510(k) submission, with no major vulnerabilities found and strong validation of its cy-ber-security framework. The company also introduced enhanced encrypted identification tags and firmware protections to safeguard donor data and ensure test integrity. Leadership emphasized these milestones as evidence of exceeding regulatory expectations and proactively addressing evolving FDA cy-ber-security guidance. By reinforcing security early, INBS strengthens its submission prospects and positions its non-invasive testing technology for potential clearance, unlocking significant growth opp's in the large U.S. drug screening market. #4. Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry. Intelligent Bio Solutions announced successful manufacturing and shipment of its Intelligent Fingerprinting Drug Screening Readers through its Syrma Johari partnership, marking a major step in scaling production and preparing for U.S. market entry. The collaboration expands capacity fourfold, meets global quality standards, and supports growing demand across Europe. The company also doubled in-house test strip production, enhancing vertical integration and innovation. These efficiencies are expected to reduce costs by over 40% and boost gross margins significantly, positioning INBS for pro-fit-able growth, stronger commercialization, and sustained competitive advantage in global markets ahead. #5. Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year. Intelligent Bio Solutions Inc. reported a 48% year-over-year revenue increase for its fiscal second quarter, with reader sales soaring 104%. First-half 2026 revenue exceeded $2Mn, marking 36% annual growth. The company’s razor-razorblade sales model—driven by hardware placements and recurring cartridge sales—is fueling sustained pro-fit-ability, with gross pro-fit margins rising to 49%. Supported by $9.4Mn in new capital, INBS’s strong financial position and expanding installed base underscore its growing market demand, operational efficiency, and progress toward U.S. regulatory clearance and commercial expansion. ----- We've one again kicked off coverage on Intelligent Bio Solutions Inc. (Nasdaq: INBS). As soon as updates are ready, we'll send them out quickly. Talk soon. All the best, Dane James Editor Market Pulse Today Sources: INBS Website INBS Presentation (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 04/20/2026 and ending on 04/20/2026 to publicly disseminate information about (INBS:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid thirty two thousand five hundred USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (INBS:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/inbs-aiwop/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice